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Abstract
In last two decades newer therapies in cancer
treatment have emerged and have opened new horizons.
New term of targeted therapy has emerged and for certain
malignancies the paradigm has really changed after the
introduction of these agents. We have learnt and have seen
the outcome of some diseases after the addition of these
monoclonal antibodies (MoABs) and tyrosine kinase
inhibitors (TKIs).
Rituximab a MoAB against CD-20 has really paved
its role in the treatment of B-cell lymphomas and become
the sort of standard therapy. The TKIs are newer agents
available in a pill form and have inhibited many pathways
at cellular level which are necessary for cancer
development. Imatinib has really changed the prognosis and
outcome of chronic myeloid leukemia (CML) remarkably.
For those patients who develope intolerance to imatinib or
their disease became resistant to the imatinib the newer
agents like dasatinib and nilotinib are second line options. 
The major edge of these newer agents is more
potency with low side-effect profile. The major concern
remains the cost.
Introduction
Cancer treatment has been revolutionized by the
identification of specific targets on cancer cells and
henceforth the development of what is called the Targeted
therapy. The concept of targeted therapy is derived from the
idea of a "magic bullet," first elaborated by Paul Erlich in
the late 1800s, when he described a chemical with the
ability to specifically target microorganisms.1 In cancer
treatment, they hold a promise of lesser toxicity and better
treatment outcomes, which has been proven so far in
lymphomas, leukaemias and a list of solid tumours, ranging
from breast to brain cancers. The toxic profile of many
cancer drugs and greater understanding of the molecular
biology involved in cancer evolution gradually paved the
way for development of the targeted agents over the past
half of the century, to quote an example, discovery of
Philadelphia chromosome and subsequent availability of a
targeted agent like imatinib for cure has virtually changed
the outcome of patients with CML.2
Of all targets at cellular levels the oldest known are
hormone receptors, the estrogen and progesterone receptors
expressed on breast tumors. Over the time targets like CD-
20, CD-57, epidermal growth factor receptor (EGFR)
family of receptors and the vascular endothelial growth
factor (VEGEF) receptors have been  identified and their
link to development and dissemination of cancer have been
confirmed. Tamoxifen an estrogen receptor modulator has
established significant therapeutic effects in hormone
positive breast cancers.3,4 Similarly, efficacy of
trastuzumab, a monoclonal antibody against Her2 receptor
(EGFR 2) on breast tumour cells has also been proven
scientifically.4
The Modern targeted therapy is broadly divided in
two groups, The MoABs and the TKI. MoABs are
specifically designed to attach with a receptor expressed on
cell surface to inhibit the receptor associated actions, while
the TKIs inhibit the tyrosine kinase dependent cascade of
reaction that result in cancer cell proliferation.
Tyrosine Kinases (TK) are basically enzymes which
act in transferring the phosphorus to polypeptides. A human
genome contains 90 TKs and 43 TK like genes. Thus all
TKs tightly regulate important cellular mechanisms like
survival, motility, proliferation and differentiation. Tyrosine
kinase receptor typically has a extracelluar ligand binding
site, a transmembrane link and an intracellular domain,
allowing  at least three targets to be available for a hit.5
TKs are quiescent until a ligand binds to the receptor
leading to activation of complicated interwoven orchestra of
events in cytoplasm and the nucleus. As TKs are regulated
at many levels so it is not surprising that dysregulation at
many levels can lead to cancer development. These
dysregulatory mechanisms usually get activated after
chromosomal abnormalities like translocations and
mutations.  A dysregulation in the tyrosine kinase receptors
may result in cancer cell growth, increased invasiveness and
vascularity leading to dissemination, and in addition a trend
towards decreased apoptosis, all contributing to disease
progression.5
TKIs help do the opposite, and hence control the
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disease. The  dysregulatory pathways can be inhibited at
several levels like inhibition of catalytic activity, blocking
the dimerization of receptors and binding of ligands,
increased internalization of receptors and antibody
mediated cytotoxicity.5
A review of the targeted agents currently approved
for use in different cancer scenarios is presented here
(Table).
Rituximab:
Rituximab is a MoAB against CD-20 antigen, which
is expressed on mature B-lymphocytes. Rituximab exerts its
antitumour activity through cell mediated cytotoxicty,
increasing apoptosis and complement dependent cell lysis.6
Rituximab not only sensitize lymphoma cells to
chemotherapy but also has synergistic activity.7
Rituximab for Non Hodgkin's Lymphomas
(NHL):
A large randomized trial by GELA (Groupe d'Etude
des Lymphomes de l'Adulte) established the role of
rituximab in the therapy of DLBCL in elderly patients.
Patients were randomized to receive rituximab with
standard CHOP (R-CHOP, n=202) or CHOP (n=196). After
2 years of follow-up results favoured R-CHOP arm with
event free survival (EFS, p <0.001) (Figure-1), over all
survival (OS, p=0.007) (Figure-2) and complete responses
(CR, p=0.005). Addition of rituximab also reduced the risk
of death and time to treatment failure (TTF).8
MabThera International Trial (MInT), a randomized,
multinational trial used R-CHOP or CHOP like
chemotherapy in younger patients diagnosed with DLBCL.
Patients were randomized to receive rituximab with CHOP
like chemotherapy (n = 413) and chemotherapy alone (n =
411). With median follow-up of 34 months EFS was 20%
higher for rituximab arm (p<0.001). Progression free
survival (PFS, p<0.001) and OS 93% vs. 84% (p < 0.0001)
also favoured combination therapy.9
Rituximab alone or with chemotherapy has
established role in treatment of indolent lymphomas.
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Table: Approved indications and side effect 
Drug Name FDA Approval Approved Indications Side Effect Profile
Rituximab November 1997
Tositumomab June 2003
Alemtuzumab September 2007
Imatinib May 2001
Dasatinib June 2006
Nilotinib October 2007
NHL* = Non Hodgkins Lymphoma, CML+ = Chronic Myeloid Leukemia (URL http://www.cancer.gov/cancertopics)
Follicular Lymphoma, CD 20+ NHLs*,
Rheumatoid Arthritis.
Relapsed follicular Lymphoma.
B-Chronic Lymphocytic Leukaemia.
Philadelphia chromosome positive CML+.
Relapsed or refractory Philadelphia chromosome
positive ALL. Gastrointestinal stromal tumor.
Dermatofibrosarcoma protuberans.
Imatinib resistant or intolerant CML in chronic
phase, accelerated phase or blast crisis.
Imatinib resistant or intolerant CML in chronic
phase or accelerated phase.
Anaphylaxis, B-Cell depletion, activation of viral
infection, unexplained prolonged neutropenia.
Myelosupression, B-cell depletion,
hypothyroidism, second cancers.
Myelosupression, sever or fatal bacterial
infections, activation of viral infections.
Myelosupression, edema, muscle crampes,
diarrhea and  nausea.
Myelosupression, pleural effusion, diarrhea,
peripheral edema, headache and disturbed liver
function
Myelosupression, deranged liver function tests
and skin rash.
Figure-1: Event-free Survival among 399 Patients Assigned to Chemotherapy with
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with
CHOP plus Rituximab. (With permission from Ref. No. 8).
Follicular lymphoma and mantle cell lymphoma (MCL) are
well known for recurrences and good initial responses to
chemotherapy.
Chemotherapy naive patients with stage III or IV
follicular lymphoma were treated with R-CVP or CVP
alone. Responses were significantly better with R-CVP [CR
41% vs. 10% (p< 0.0001), TTF p<0.0001)].7
German Low-Grade Lymphoma Study Group
(GLSG) compared R-CHOP and CHOP in patients with
advanced stage follicular lymphoma. With median follow-
up of 18 months significant trends were observed in regard
of TTF (p <0.001), longer remission (p <0.001), treatment
free interval (p=0.001) and OS (p=.016).10
Maintenance rituximab for Non Hodgkins
Lymphomas:
Intergroup trial evaluated the role of maintenance
rituximab in older patients (>60 years) after induction
therapy with CHOP and R-CHOP. Patients treated with R-
CHOP had better failure free survival (FFS) of 53% vs. 46%
(p = 0.009). Beneficial effect of maintenance rituximab was
more evident in patients who received CHOP (p = 0.0004)
vs. R-CHOP (p = 0.81) as induction therapy. Maintenance
rituximab did not improve the OS.11
GLSG performed a trial on patients with
refractory/relapsed follicular lymphoma and MCL. Patients
were randomized to receive fludarabine,
cyclophosphamide, mitoxantrone (FCM) or R-FCM. Over
all response rates (ORR = 79% vs. 58% p = 0.01) and CR
(33% vs. 13%; p= 0.005) were better for R-FCM group, for
both follicular lymphoma and MCL.12 Responding patients
were than assigned to maintenance rituximab vs.
observation. Patients with follicular lymphoma, who
received maintenance rituximab had prolonged duration of
response with estimated 26 months (p= 0.035). For patients
with MCL difference of 2 months was noted (p= 0.049).
More patients will be alive in maintenance arm at 3 years
(77% vs. 57%, p= 0.1).13
In multicenter, intergroup trial patients with
resistant/relapsed follicular lymphoma were randomized to
R-CHOP (n=234) and CHOP (n=231) arms. ORR (85.1%
vs. 72.3%) and CR (29.5% vs. 15.6%, p= 0.001) were better
for patients assigned to R-CHOP arm. The responders were
then randomized to 2 years of maintenance rituximab
(n=167) or observation (n= 167). Median PFS of 51.5
months vs. 14.9 months was observed for patients on
maintenance rituximab arm (p= 0.001). Maintenance
rituximab improved median PFS to 42.2 months vs. 11.6
months after induction with CHOP [hazard ratio (HR), 0.30;
p = 0.001] and to 51.8 months vs. 23 months after induction
with R-CHOP (HR, 0.54; p = 0.004). Three years OS of
85.1% and 77.1% was demonstrated for maintenance
rituximab and observation groups respectively.14
Rituximab for Chronic Lymphocytic
Leukaemia (CLL):
Most common haematological malignancy in adults
is CLL. Combination of rituximab and fludarabine has
better responses as compare to fludarabine alone. 
In a retrospective analysis of 2 studies, performed by
Cancer and Leukaemia Group B (CALGB 9712 and
CALGB 9011) better PFS and OS were seen for patients
who were treated with rituximab and fludarabine. Patients
treated with combination therapy had significant CR (0.38
vs. 0.20, p= 0.002), ORR (0.84 vs. 0.63, p = 0.0003) and OS
(p = 0.003).15
Keating et al used combination of rituximab,
fludarabine and cyclophosphamide as initial therapy in
patients with CLL. Out of 224 treated patients, 156 attained
CR (70%), 23 (10%) achieved nodular PR (NPR), and PR
in 34 (15%) patients. Of 156 patients with CR, 154 were
alive till July 2003. Advanced stage, high leukocyte counts,
thrombocytopenia, increased ß-2 microglobulin levels,
enlarged spleen, bone marrow cellularity of >50% and old
age were the confounding factors for poor response.16
Rituximab for Graft versus Host Disease
(GVHD):
Around one third of long term survivors of
allogeneic stem cell therapy (SCT), succumb to chronic
GVHD. One of the postulated underlying mechanisms for
chronic GVHD is immune mediated donor T cell reactions,
but depletion of T cells did not translate to decreased
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Figure-2: Overall Survival among 399 Patients Assigned to Chemotherapy with
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with
CHOP plus Rituximab. (With permission from Ref. No. 8).
incidence of chronic GVHD. Increasing evidence is
suggesting that B cells have some underlying role in
pathophysiology for GVHD. 
Rituximab was administered to 21 patients with
steroid refractory chronic GVHD. Responses were seen in
12 (70%) patients with CR for 2 patients. Significant
decrease (p= 0.001) in steroid dose was observed.
Improvement in cutaneous and musculoskeletal symptoms
was observed at the end of one year.17
With these encouraging results rituximab has
changed the paradigm in treatment of B cell NHLs. Ever
increasing indications are coming up and rituximab is being
used for immune mediated thrombocytopenic purpura,
autoimmune haemolytic anaemia, rheumatoid arthritis and
pemphigus vulgaris.6
Tositumomab:
Tositumomab, a murine IgG2a antibody which when
labeled with radioactive Iodine-131; attacks surface CD-20
receptors on B-cells. It further improves the responses
attained with rituximab by virtue of having a radioactive
substance (I 131) attached to it.
Improved responses may be because of addition of
radiation effects, which not only kill the cell it is attached
with but also destroy the surrounding cells; together with
the cytotoxic and apoptosis properties of the antibody. 131I
tositumomab exerts its effects with antibody-mediated
actions of tositumomab and ionizing effects of I-131.
Because decaying iodine-131 releases short range ß
particles and ? rays, it is possible to calculate exact delivery
dose to the cancer cells and minimizing adverse effects.18
In a phase III, multicenter study, patients with
refractory low grade B-cell NHL received single dose of
131I tositumomab. Patients had to receive chemotherapy
with proven efficacy in NHL, before getting the radio
labeled therapy. Responses were compared between the
responses obtained after last chemotherapy and after iodine
labeled therapy. Better responses were observed after 131I
tositumomab than after last chemotherapy (65% vs. 28%; p
= 0.001). CR (20% vs. 3%) and median PFS (8.4 months vs
6.3 months) were significantly better for patients treated
with 131I tositumomab as compared to chemotherapy.18
South West Oncology Group started a phase II trial
to assess the efficacy and safety of 131I tositumomab after
induction therapy with 6 cycles of CHOP in patients with
newly diagnosed follicular lymphoma. More than two third
of patients had stage IV disease. Of 90 eligible patients, 77
received full protocol therapy. CR achieved by 49 (54%)
patients, CRu in 11 (12%) and PR in 21 (23%) after
completion of planned therapy with CHOP plus 131I
tositumomab. Objective response of 90% was obtained.
Four patients (9%) with CRu after CHOP achieved CR with
131I tositumomab, and 23 (49%) patients attained CRu or
CR after radioactive therapy. Estimated 2 years PFS and OS
were 81% and 97% respectively.19
Alemtuzumab:
Alemtuzumab is a humanized monoclonal antibody
with activity against CD-52 expressing lymphocytes. CD-
52 antigen is expressed on almost every B and T
lymphocyte, normal or malignant and is also present on
monocytes and macrophages. Alemtuzumab has been
approved for fludarabine refractory B-CLL.20After binding
specifically with CD-52, it exerts it effects through
complement activation apoptosis and antibody dependant
cell mediated toxicity.20-22
Alemtuzumab for Chronic Lymphocytic
Leukaemia (CLL):
Patients with CLL refractory to fludarabine were
treated with alemtuzumb in a phase II trial. A total of 93
patients were enrolled and after 12 weeks of therapy, ORR
of 33% (CR = 2% and PR = 31%) was achieved. Median
survival of 16 months and median response duration of 8.7
months were observed. Twenty five patients, experienced
severe infection with sepsis in 14 patients. Support with
colony stimulating growth factor was required by 35%
patients.23
In a randomized, multicenter, phase III trial, patients
were randomized to receive alemtuzumab (n= 149) or
chlorambucil (n=148) as first line therapy for CLL. ORR
(83.2% vs. 55.4%, p = 0.0001), CR (24.2% vs. 2%, p =
0.0001), minimal residual disease (MRD, 7.4% vs. 0%, p =
0.0008), time to start 2nd therapy (88 weeks vs. 36 weeks)
favored alemtuzumab. PFS was also better with
alemtuzumab (p= 0.0001). OS has not been reached for both
the arms after a median follow-up of 2 years. Infusion
related AEs, haematological toxicities and more CMV
activation events were seen with alemtuzumab.24
Moreton P et al assessed the effect of elimination of
MRD after treatment with alemtuzumab on survival. Of 91,
majority of patients were heavily pretreated including
purine analogues. ORR was achieved 53% patients with CR
for 35% (MRD+ = 15% and MRD- = 20%) and PR for 19%.
Of 18 patients who achieved MRD- remission, 13 had no
lymphadenopathy on presentation and 16 (88%) were alive
with a median follow-up of 36 months. Treatment free
survival (TFS) and OS were substantially higher for patients
who attained MRD- CR.21
To assess the effect of combination of alemtuzumab
and rituximab, 48 patients with relapsed/refractory
lymphoid malignancies were treated. Bone marrow was
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involved in 44 patients and 32 had CLL. Responses were
observed in 52% patients with CR for 8%, nodular PR for
4% and PR for 40%. SD or progression was seen in
remaining 23 patients. Median OS for responding patients
was 11 months compare to 6 months for non responders.25
Alemtuzumab for Mycosis Fungoides and
Se´zary Syndrome (MF/SS):
Mycosis fungoides and Se´zary syndrome are one of
common cutaneous lymphomas, usually with indolent
course. But these may infiltrate peripheral blood, lymph
nodes and other viscera. Patients with MF/SS usually die of
septicemia secondary to suppressed cell mediated immunity
and skin disruption. 
In a phase II trial, 22 patients with relapsed MF/SS
received alemtuzumab for 12 weeks. CR was achieved for 7
patients, PR for 5, SD for 3 and progressive disease (PD)
was seen in 7 patients. Median TTF was 12 months for
responding patients.22
Imatinib:
Imatinib mesylate a TKI inhibits multiple TKs,
including ABL, BCR-ABL, platelet-derived growth factor
receptor (PDGFR), and c-kit. Imatinib induces apoptosis of
BCR-ABL+ cells as it halts the downstream signals for
growth by preventing the phosphorylation of BCR-ABL.
FDA approved imatinib in May 2001 for the treatment of
CML.
Imatinib in Chronic Myeloid Leukaemia
(CML):
CML is a myeloproliferative disorder which is
characterized by clonal abnormality of haematopoietic cells
after a balanced translocation of chromosomes 9 and 22,
[t(9;22)(q34;q11)] also known as Philadelphia (Ph)
chromosome. Most of the times, patients get diagnosed with
high leucocyte counts. CML has chronic phase (CML-CP),
accelerated phase (CML-AP) and an aggressive blast crisis.
The median survival for CML-CP was 3-5 years and 6
months for blast crisis before the introduction of imatinib.
Hydroxyurea, interferon, cytarabine and allogenic SCT
were the treatment options. Patients with complete
cytogenetic response (CCyR) had higher survival as
compare to patients who do not attain that.26
The IRIS (International Randomized Study of
Interferon and STI571) trial is a randomized, multicentre,
phase III trial, which compared the efficacy of imatinib with
interferon alfa and low dose cytarabine. A total of 1106 (553
in each group) patients were randomized to receive imatinib
at 400 mg orally daily or interferon alfa with subcutaneous
cytarabine. Primary end point was progression and
secondary endpoint was complete haematologic response
(CHR). With the median follow-up of 19 months more
patients in imatinib group achieved CHR (95.3% vs. 55.5%,
p<0.001) and major cytogentic respone (MCyR, 85.2% vs.
22.1%, p<0.001). PFS (92.1% vs. 73.5%, p<0.001) and
estimated OS (97.2% vs. 95.1%, p = 0.16) favoured
imatinib therapy.27
After a median follow-up of 5 years of this study,
69% of patients in imatinib group were on treatment while
only 3% in combination therapy group. More patients in
immunotherapy arm crossed over to imatinib arm (65% vs.
3%). The most common reason being the intolerance to
therapy. MCyR were observed by 89% patients while 82%
patients achieved CCyR (Figure-3). Patients with CCyR at
12 months in imatinib group (97%), did not progress to AP
or blast crisis after 5 years of median follow-up. Estimated 5
year survival was 89% for imatinib arm. The most common
AEs were edema (60%), muscle cramps (49%), diarrhoea
(45%), nausea (50%), grade 3 or more neutropenia (17%),
thrombocytopenia (9%) and anaemia (4%).28
Imatinib in Acute Lymphocytic Leukaemia
(ALL):
Adult patients with ALL have poor out-come even
with SCT as compare to children and adolescence. The
reasons are drug resistance, poor compliance and
acceptance and molecular abnormalities. BCR-ABL fusion
has been observed in 3% of children diagnosed with ALL
Vol. 59, No. 8, August 2009 559
Figure-3: Kaplan-Meier Estimates of the Cumulative Best Response to Initial
Imatinib Therapy.
At 12 months after the initiation of imatinib, the estimated rates of having a
response were as follows: complete hematologic response, 96%; major cytogenetic
response, 85%; and complete cytogenetic response, 69%. At 60 months, the
respective rates were 98%, 92%, and 87%. Data for patients who discontinued
imatinib for reasons other than progression and who did not have an adequate
response were censored at the last follow-up visit. Data for patients who did not
have an adequate response and who stopped imatinib because of progression were
censored at maximum follow-up. (With permission from Ref: # 28).
and increases to 20% for adults and even >50% in patients
>50 years.29
Adult patients with Ph+ ALL entered a phase II trial
and were treated with chemotherapy and imatinib. Imatinib
was added to consolidation chemotherapy before
proceeding to allo- or autologuous SCT. Of 45 patients 43
patients achieved CR. OS of 65% and DFS of 51% were
observed at median follow-up of 18 months. Advanced age
was associated with poor OS.30
Gruppo Italiano Malattie Ematologiche dell'Adulto
(GIMEMA) enrolled 30 elderly patients with diagnosis of
Ph+ ALL in a phase II trial. Patients were treated with
imatinib and steroids. After 45 days of therapy all patients
achieved CHR with median duration of response of 8
months and median survival of 20 months.31
Imatinib in Acute Myelogenous Leukaemia
(AML):
The prognosis of AML depends on age, karyotype
and post-induction regimen. After treatment with
daunorubicin and cytarabine chemotherapy, 5 year OS is
40% for patients <60 years and only 6%-15% for older
patients. Allogenic SCT is an option for patients with
refractory AML but because of procedure associated
morbidity and limitation of available matched donor; most
patients are not eligible for this treatment. For the
maintenance of normal haematopoiesis, c-kit plays an
important role. c-kit activity has been seen in certain human
malignancies including AML. Besides other targets imatinib
inhibits c-kit associated signals as well. 
In an open label, phase II study patients with
refractory or newly diagnosed AML were treated with
imatinib only. Of 21 patients 2 achieved CHR, 1 had no
evidence of leukaemia and 2 patients achieved sustained
minor response.32
Imatinib is standard of care for patients with the
diagnosis of CML. It has established its role in
gastrointestinal stromal tumour (GIST) as well.
Dasatinib:
Despite on imatinib some patients with CML
develop resistance due to new mutations or they just cannot
tolerate imatinib. Dasatinib is another oral ABL kinase
inhibitor. Dastinib has the property of binding active and
inactive domain and it also has activity for imatinib resistant
domains.
In a phase I, open label study 40 patients with CML-
CP, 11 with CML-AP, 23 with myeloid blast crisis, and 10
with lymphoid blast crisis or Ph+ ALL were registered to
receive dasatinib. Of 40 patients with CML-CP, 92%
attained CHR with 45% MCyR. For patients with CML-AP
or blast crisis or ALL the CHR was seen in 70%. Grade 3 or
4 myelosuppresion was common AEs requiring dose
reduction or treatment interruption. Other AEs were pleural
effusion, diarrhoea, peripheral edema, headache and
disturbed liver function.33
In a multinational, phase II trial, 107 patients with
imatinib resistant or intolerant CML-AP were treated with
dassatinib at 70 mg twice daily. Primary end point of the
study was the major and over all haematologic responses
(OHR). After 8 months of follow-up, 69 patients achieved
major haematologic response with CHR for 42 patients.
OHRs were observed in 81% patients and MCyR in 33%
patients. Pleural effusion developed in 25 patients. Grades 3
or 4 pancytopenia were present at the start of therapy in
some patients and almost every patient observed some
degree of cytopenias while on therapy.34
Nilotinib:
Nilotinib is a new TKI which is more potent than
imatinib aginst CML. It inhibits competitively the binding
site of BCR-ABL with 20-50 times higher activity than
imatinib and is also active in patients with imatinib resistant
CML.
In a phase I dose escalation study, 119 patients
imatinib resistant CML or ALL were registered. Patients
were treated with escalating doses of nilotinib starting from
50 mg once daily to 600 mg twice daily. Of all 33 patients
with blast phase CML, 13 patients achieved haematologic
response with MCyR for 6 patients. Among 46 patients with
CML-AP, 33 had haematologic response with MCyR for 9
patients and of 17 patients with CML-CP, 11 achieved CHR
and 6 patients attained CCyR. Of 10 patients with Ph+ ALL,
1 observed partial haematologic response and 1 among 3
patients with Ph+ ALL with persistent molecular signs
attained complete molecular response. Grade 3-4
thrombocytopenia, neutropenia and deranged liver function
tests were major toxicites.35
Conclusion
The treatment paradigms in cancer therapy have
been redefined by the introduction of targeted therapies.
Their fair toxicity profile, ease of administration, molecular
basis of action and proven efficacy in phase III trials make
them an attractive choice. Their cost however remains there
downside. In developing countries there would be an
imperative need to use these agents judiciously and properly
by identifying the patient population that might benefit from
this form of therapy.
Increasing understanding of molecular basis of
cancer promises greater discoveries in the treatment of
cancer and perhaps finer targeted therapies as well. Indeed
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with such a rapid advance the future of patient tailored
therapy does not look like a distant dream.
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